Abstract
Radioimmunotherapy (RIT†) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Hodgkin's lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation of RIT. The predominant complication of RIT is hematological toxicity that is usually manageable. There are ongoing trials to further define the expanding role of RIT as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role of RIT in treatment of non-Hodgkin's lymphoma, which is of established clinical utility and FDA approved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 391-407 |
| Number of pages | 17 |
| Journal | Yale Journal of Biology and Medicine |
| Volume | 84 |
| Issue number | 4 |
| State | Published - Dec 1 2011 |
Fingerprint
Keywords
- Alpha particle
- Auger
- Beta particle
- Bexxar
- Biodistribution
- Dosimetry
- Hodgkin's lymphoma
- Immunotherapy
- Lymphoma
- Monoclonal antibody
- Non-Hodgkin's lymphoma
- Radioimmunotherapy
- Rituximab
- Y-90
- Zevalin
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Radioimmunotherapy of non-Hodgkin's lymphoma : From the 'magic bullets' to 'radioactive magic bullets'. / Chamarthy, Murthy R.; Williams, Scott C.; Moadel, Renee M.
In: Yale Journal of Biology and Medicine, Vol. 84, No. 4, 01.12.2011, p. 391-407.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Radioimmunotherapy of non-Hodgkin's lymphoma
T2 - From the 'magic bullets' to 'radioactive magic bullets'
AU - Chamarthy, Murthy R.
AU - Williams, Scott C.
AU - Moadel, Renee M.
PY - 2011/12/1
Y1 - 2011/12/1
N2 - Radioimmunotherapy (RIT†) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Hodgkin's lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation of RIT. The predominant complication of RIT is hematological toxicity that is usually manageable. There are ongoing trials to further define the expanding role of RIT as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role of RIT in treatment of non-Hodgkin's lymphoma, which is of established clinical utility and FDA approved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
AB - Radioimmunotherapy (RIT†) of lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Hodgkin's lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation of RIT. The predominant complication of RIT is hematological toxicity that is usually manageable. There are ongoing trials to further define the expanding role of RIT as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role of RIT in treatment of non-Hodgkin's lymphoma, which is of established clinical utility and FDA approved. The mechanism of RIT, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
KW - Alpha particle
KW - Auger
KW - Beta particle
KW - Bexxar
KW - Biodistribution
KW - Dosimetry
KW - Hodgkin's lymphoma
KW - Immunotherapy
KW - Lymphoma
KW - Monoclonal antibody
KW - Non-Hodgkin's lymphoma
KW - Radioimmunotherapy
KW - Rituximab
KW - Y-90
KW - Zevalin
UR - http://www.scopus.com/inward/record.url?scp=84863393240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863393240&partnerID=8YFLogxK
M3 - Review article
VL - 84
SP - 391
EP - 407
JO - Yale Journal of Biology and Medicine
JF - Yale Journal of Biology and Medicine
SN - 0044-0086
IS - 4
ER -